Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CareDx, Inc (CDNA)
USD29.17
+0.24 (+0.81%)
US NASDAQ Healthcare Medical - Diagnostics & Research
Address
1 Tower Place 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
John Walter Hanna Jr.
Website
caredx.com
IPO
2014-07-17
CIK 1217234 ISIN US14167L1035
Description
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
News Sentiment (7d)
Based on only 2 articles — low confidence
- CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder Seeking Alpha
- CareDx Completes Naveris Acquisition and Expands Oncology Reach Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD29.17
+0.24 (+0.81%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
814.9K
Beta
2.48
Float Shares
49.29M
Free Float %
95.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.53% | +4.92% | +9.66% | +21.64% | +27.70% | +21.13% | +34.31% | +186.32% | -72.20% | +413.96% | +152.15% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
29.17
Low
18.00
-38.3%
Consensus
24.00
-17.7%
Median
26.00
-10.9%
High
28.00
-4.0%
Ratings Trend (MoM)
43% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 4 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
28.00
-4.0%
|
| Last Year | 4 |
24.50
-16.0%
|
| All Time | 12 |
30.33
+4.0%
|
Quality scores
Altman Z-Score
5.83
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+13.8% ★ Q1'26: +39.0% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-143.0% Q1'26: +126.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-0.8% Q1'26: +0.4% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-5.6% Q1'26: +1.5% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-14.5% Q1'26: +5.0% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-5.9% ★ Q1'26: -3.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-29.50× Q1'26: 0.63× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
28.14M
est: 28.93M (-2.7%)
|
40.63M
est: 40.50M (+0.3%)
|
48.32M
est: 48.07M (+0.5%)
|
76.57M
est: 76.10M (+0.6%)
|
127.07M
est: 127.03M (+0.0%)
|
192.19M
est: 189.06M (+1.7%)
|
296.40M
est: 294.49M (+0.6%)
|
321.79M
est: 321.02M (+0.2%)
|
280.32M
est: 297.08M (-5.6%)
|
333.79M
est: 331.35M (+0.7%)
|
379.81M
est: 374.60M (+1.4%)
|
455.96M
455.55M – 456.36M
+21.7% YoY
|
481.29M
481.03M – 481.54M
+5.6% YoY
|
507.21M
492.95M – 516.02M
+5.4% YoY
|
| EBITDA |
-11.26M
est: -4.04M (-179.0%)
|
-17.85M
est: -5.65M (-215.8%)
|
-14.61M
est: -6.71M (-117.8%)
|
-11.36M
est: -10.62M (-7.0%)
|
-17.39M
est: -17.73M (+1.9%)
|
-8.17M
est: -40.24M (+79.7%)
|
-17.84M
est: -58.29M (+69.4%)
|
-61.22M
est: -44.80M (-36.7%)
|
-84.92M
est: -39.04M (-117.5%)
|
-34.00M
est: -43.54M (+21.9%)
|
-667.0K
est: -49.22M (+98.6%)
|
-59.91M
-59.96M – -59.86M
-21.7% YoY
|
-63.24M
-63.27M – -63.21M
-5.6% YoY
|
-66.65M
-67.80M – -64.77M
-5.4% YoY
|
| EBIT |
-12.06M
est: -5.60M (-115.5%)
|
-24.77M
est: -7.83M (-216.2%)
|
-18.34M
est: -9.30M (-97.2%)
|
-15.58M
est: -14.72M (-5.8%)
|
-24.53M
est: -24.57M (+0.2%)
|
-17.72M
est: -80.97M (+78.1%)
|
-29.73M
est: -96.75M (+69.3%)
|
-77.23M
est: -62.10M (-24.4%)
|
-104.74M
est: -55.29M (-89.5%)
|
-53.75M
est: -61.66M (+12.8%)
|
-21.08M
est: -69.71M (+69.8%)
|
-84.85M
-84.93M – -84.78M
-21.7% YoY
|
-89.57M
-89.61M – -89.52M
-5.6% YoY
|
-94.39M
-96.03M – -91.74M
-5.4% YoY
|
| Net Income |
-13.71M
est: -63.04M (+78.3%)
|
-39.47M
est: -53.98M (+26.9%)
|
-55.47M
est: -49.68M (-11.6%)
|
-46.76M
est: -74.32M (+37.1%)
|
-21.97M
est: -31.85M (+31.0%)
|
-18.71M
est: -70.38M (+73.4%)
|
-30.66M
est: -107.26M (+71.4%)
|
-76.61M
est: -80.84M (+5.2%)
|
-190.28M
est: -159.64M (-19.2%)
|
52.55M
est: -48.71M (+207.9%)
|
-21.35M
est: -15.91M (-34.2%)
|
49.38M
47.91M – 50.85M
+410.4% YoY
|
59.97M
58.19M – 61.76M
+21.5% YoY
|
80.96M
78.55M – 83.37M
+35.0% YoY
|
| SGA |
20.60M
est: 17.31M (+19.0%)
|
31.89M
est: 24.23M (+31.6%)
|
31.72M
est: 28.76M (+10.3%)
|
43.63M
est: 45.53M (-4.2%)
|
75.43M
est: 76.00M (-0.7%)
|
102.66M
est: 113.12M (-9.2%)
|
152.21M
est: 176.20M (-13.6%)
|
196.42M
est: 192.07M (+2.3%)
|
201.20M
est: 178.89M (+12.5%)
|
205.50M
est: 199.53M (+3.0%)
|
210.21M
est: 225.57M (-6.8%)
|
274.56M
274.32M – 274.80M
+21.7% YoY
|
289.81M
289.66M – 289.97M
+5.6% YoY
|
305.43M
296.84M – 310.73M
+5.4% YoY
|
| EPS |
-1.16
est: -1.11 (-4.2%)
|
-2.39
est: -0.95 (-150.7%)
|
-2.38
est: -0.88 (-171.2%)
|
-1.31
est: -1.31 (+0.2%)
|
-0.52
est: -0.56 (+7.6%)
|
-0.40
est: -0.48 (+16.0%)
|
-0.59
est: -0.30 (-99.3%)
|
-1.44
est: -1.43 (-0.7%)
|
-3.54
est: -3.02 (-17.2%)
|
1.00
est: -0.90 (+211.7%)
|
-0.40
est: -0.30 (-34.0%)
|
0.93
0.90 – 0.95
+412.5% YoY
|
1.13
1.09 – 1.16
+21.5% YoY
|
1.53
1.47 – 1.56
+35.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-29 | BTIG | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
76.33M
OE per share TTM
1.44
Owner's Yield
6.54%
Maintenance CapEx ratio
61.28%
Maint CapEx / Avg PPE
16.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
190
Total invested
911.99M
Insider transactions (90d)
5
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 5.79M | 10.83% | 5.79M | — | 5.79M | — | IA | Delaware, United States | 2022-10-11 | ↗ |
| 2 | Alger Group Holdings, LLC | 5.35M | 10.87% | 5.35M | — | 5.35M | — | HC | New York | 2021-02-16 | ↗ |
| 3 | Fred Alger Management, LLC | 5.35M | 10.87% | 5.35M | — | 5.35M | — | IA | New York | 2021-02-16 | ↗ |
| 4 | The Vanguard Group - 23-1945930 | 5.27M | 9.98% | — | 96.4K | 5.13M | 142.5K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 5 | Fred Alger & Company, Incorporated – 13-2665689 | 4.20M | 10.31% | 4.20M | — | 4.20M | — | BD | New York | 2019-02-14 | ↗ |
| 6 | ArrowMark Colorado Holdings, LLC | 4.00M | 7.48% | 4.00M | — | 4.00M | — | IA | Delaware, United States | 2023-02-15 | ↗ |
| 7 | (1) BlackRock, Inc. | 3.90M | 7.40% | 3.85M | — | 3.90M | — | HC | Delaware | 2022-02-03 | ↗ |
| 8 | NEIL GAGNON | 3.35M | 6.20% | 169.9K | 2.79M | 169.9K | — | IN | USA | 2023-03-13 | ↗ |
| 9 | Alger Associates, Inc. 13-3017981 | 3.27M | 6.20% | 3.27M | — | 3.27M | — | HC | New York | 2022-02-14 | ↗ |
| 10 | Bellevue Asset Management (UK) Ltd. | 3.17M | 5.90% | — | 3.17M | — | 3.17M | FI | — | 2023-02-14 | ↗ |
| 11 | Bellevue Group AG | 3.17M | 5.90% | — | 3.17M | — | 3.17M | HC, CO | — | 2023-02-14 | ↗ |
| 12 | Nikko Asset Management Americas, Inc. | 2.87M | 5.31% | — | 2.03M | — | 2.87M | IA | USA | 2024-02-12 | ↗ |
| 13 | Nikko Asset Management Co., Ltd. (“NAM”) | 2.87M | 5.31% | — | 2.87M | — | — | FI, IA, HC | Japan | 2024-02-05 | ↗ |
| 14 | Sumitomo Mitsui Trust Holdings, Inc. (“SMTH”) | 2.87M | 5.31% | — | 2.87M | — | — | FI, HC | Japan | 2024-02-05 | ↗ |
| 15 | ( ) | 2.78M | 11.00% | — | — | 2.78M | — | HC | Delaware | 2020-02-14 | ↗ |
| 16 | Ivy Investment Management Company Tax ID No. 03-0481447 | 2.78M | 11.00% | 2.78M | — | — | — | IA | Delaware | 2020-02-14 | ↗ |
| 17 | 98-0557567 | 2.67M | 5.00% | 2.56M | — | 2.67M | — | IA, HC | Bermuda | 2022-02-09 | ↗ |
| 18 | GAGNON SECURITIES LLC | 2.52M | 4.70% | — | 2.14M | — | — | BD, IA | DELAWARE LIMITED LIABILITY COMPANY | 2023-03-13 | ↗ |
| 19 | STATE STREET CORPORATION | 1.85M | 3.76% | — | 1.66M | — | 1.85M | HC | BOSTON MASSACHUSETTS | 2021-02-12 | ↗ |
| 20 | Securities LLC | 1.35M | 3.20% | — | 1.17M | — | — | BD, IA | Limited Liability Company | 2019-06-20 | ↗ |
| 21 | GAGNON ADVISORS, LLC | 526.1K | 1.00% | — | 526.1K | — | — | IA | DELAWARE LIMITED LIABILITY COMPANY | 2023-03-13 | ↗ |
| 22 | Consonance Capital Management LP | — | 0.00% | — | — | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 23 | Consonance Capital Opportunity Fund Management LP | — | 0.00% | — | — | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 24 | Consonance Capman GP LLC | — | 0.00% | — | — | — | — | HC, OO | Delaware USA | 2021-02-17 | ↗ |
| 25 | Mitchell Blutt | — | 0.00% | — | — | — | — | HC, IN | USA | 2021-02-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
190
-11 vs prev Q
New positions
26
Closed positions
36
Increased
100
Reduced
58
Put/Call ratio
0.00
Calls held
20.3K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 4.65M -116.5K (-2.4%) | 87.61M +18.3M (+26.4%) | 8.86% +0.079 pp | 0.00% +0.000 pp | USD30.85 -38.9% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 3.43M -321.5K (-8.6%) | 64.59M +10.1M (+18.5%) | 6.53% -0.376 pp | 0.00% +0.000 pp | USD39.67 -52.5% | 45 qtrs — |
| 3 | BAMCO INC /NY/ | 3.16M +— (+0.0%) | 59.44M +13.6M (+29.6%) | 6.01% +0.199 pp | 0.16% +0.039 pp | USD14.18 +32.9% | 8 qtrs — |
| 4 | STATE STREET CORP | 2.74M +171.3K (+6.7%) | 51.58M +14.3M (+38.2%) | 5.21% +0.488 pp | 0.00% +0.000 pp | USD19.87 -5.2% | 32 qtrs — |
| 5 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2.19M +— (+0.0%) | 41.28M +9.4M (+29.6%) | 4.17% +0.138 pp | 0.53% +0.041 pp | USD14.54 +29.6% | 2 qtrs — |
| 6 | ARK INVESTMENT MANAGEMENT LLC | 2.14M -34.2K (-1.6%) | 40.25M +8.7M (+27.5%) | 4.07% +0.072 pp | 0.27% +0.079 pp | USD33.47 -43.7% | 27 qtrs — |
| 7 | GAGNON SECURITIES LLC | 1.77M +45.5K (+2.6%) | 33.44M +8.3M (+33.0%) | 3.38% +0.196 pp | 6.81% +1.765 pp | USD13.67 +37.8% | 46 qtrs — |
| 8 | BRAIDWELL LP | 1.59M -597.6K (-27.4%) | 29.87M -1.9M (-5.9%) | 3.02% -1.001 pp | 0.96% +0.013 pp | USD14.54 +29.6% | 2 qtrs — |
| 9 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 1.45M -293.4K (-16.9%) | 27.25M +2.0M (+7.7%) | 2.76% -0.449 pp | 0.02% +0.001 pp | USD28.07 -32.9% | 27 qtrs — |
| 10 | NIKKO ASSET MANAGEMENT AMERICAS, INC. | 1.45M -293.4K (-16.9%) | 27.25M +2.0M (+7.8%) | 2.76% -0.449 pp | 0.32% +0.070 pp | USD27.94 -32.6% | 26 qtrs — |
| 11 | DIMENSIONAL FUND ADVISORS LP | 1.31M +93.5K (+7.7%) | 24.68M +7.0M (+39.5%) | 2.49% +0.255 pp | 0.01% +0.001 pp | USD15.75 +19.6% | 26 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1.24M -53.5K (-4.1%) | 23.44M +4.6M (+24.2%) | 2.37% -0.020 pp | 0.00% +0.000 pp | USD27.89 -32.4% | 42 qtrs — |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 1.11M -50.4K (-4.4%) | 20.82M +4.0M (+23.9%) | 2.10% -0.023 pp | 0.03% +0.010 pp | USD19.57 -3.7% | 22 qtrs — |
| 14 | CHEVY CHASE TRUST HOLDINGS, LLC | 1.08M +337.6K (+45.4%) | 20.37M +9.6M (+88.4%) | 2.06% +0.690 pp | 0.06% +0.025 pp | USD17.40 +8.3% | 4 qtrs — |
| 15 | D. E. SHAW & CO., INC. | 1.04M +444.0K (+74.7%) | 19.57M +10.9M (+126.3%) | 1.98% +0.883 pp | 0.01% +0.006 pp | USD16.39 +14.9% | 31 qtrs — |
| 16 | JACOBS LEVY EQUITY MANAGEMENT, INC | 948.6K +244.5K (+34.7%) | 17.87M +7.6M (+74.6%) | 1.81% +0.510 pp | 0.07% +0.028 pp | USD14.36 +31.2% | 11 qtrs — |
| 17 | OPHIR ASSET MANAGEMENT PTY LTD | 925.4K -1.3M (-57.9%) | 17.44M -14.5M (-45.4%) | 1.76% -2.285 pp | 1.96% -1.992 pp | USD17.53 +7.5% | 4 qtrs — |
| 18 | BOSTON PARTNERS | 901.9K +870.6K (+2,776.5%) | 16.99M +16.5M (+3,627.6%) | 1.72% +1.660 pp | 0.02% +0.017 pp | USD19.06 -1.2% | 7 qtrs — |
| 19 | GOLDMAN SACHS GROUP INC | 811.2K -51.1K (-5.9%) | 15.28M +2.7M (+21.9%) | 1.54% -0.043 pp | 0.00% +0.000 pp | USD21.11 -10.8% | 46 qtrs — |
| 20 | PORTOLAN CAPITAL MANAGEMENT, LLC | 758.8K -174.8K (-18.7%) | 14.30M +721.8K (+5.3%) | 1.45% -0.274 pp | 0.77% +0.031 pp | USD17.12 +10.0% | 4 qtrs — |
| 21 | ARROWMARK COLORADO HOLDINGS LLC | 758.4K -208.5K (-21.6%) | 14.29M +229.3K (+1.6%) | 1.44% -0.336 pp | 0.31% +0.053 pp | USD17.66 +6.7% | 4 qtrs — |
| 22 | ZWEIG-DIMENNA ASSOCIATES LLC | 679.0K +104.0K (+18.1%) | 12.79M +4.4M (+53.0%) | 1.29% +0.234 pp | 0.79% +0.209 pp | USD16.87 +11.7% | 3 qtrs — |
| 23 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 665.1K -404.7K (-37.8%) | 12.53M -3.0M (-19.4%) | 1.27% -0.703 pp | 0.03% -0.016 pp | USD20.67 -8.9% | 15 qtrs — |
| 24 | CITADEL ADVISORS LLC | 642.8K +18.9K (+3.0%) | 12.11M +3.0M (+33.5%) | 1.22% +0.075 pp | 0.00% +0.000 pp | USD22.85 -17.5% | 28 qtrs — |
| 25 | ROYCE & ASSOCIATES LP | 581.2K +176.8K (+43.7%) | 10.95M +5.1M (+86.2%) | 1.11% +0.362 pp | 0.11% +0.052 pp | USD16.27 +15.8% | 45 qtrs — |
| 26 | FIRST EAGLE INVESTMENT MANAGEMENT, LLC | 546.7K +71.6K (+15.1%) | 10.30M +3.4M (+49.1%) | 1.04% +0.166 pp | 0.02% +0.006 pp | USD13.90 +35.5% | 16 qtrs — |
| 27 | MORGAN STANLEY | 541.5K +55.2K (+11.4%) | 10.20M +3.1M (+44.3%) | 1.03% +0.136 pp | 0.00% +0.000 pp | USD17.66 +6.7% | 44 qtrs — |
| 28 | GAGNON ADVISORS, LLC | 532.9K +3.5K (+0.7%) | 10.04M +2.3M (+30.4%) | 1.01% +0.040 pp | 6.37% +1.621 pp | USD13.71 +37.4% | 46 qtrs — |
| 29 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 525.0K -282.0 (-0.1%) | 9.89M +2.3M (+29.5%) | 1.00% +0.033 pp | 0.00% +0.000 pp | USD24.35 -22.6% | 31 qtrs — |
| 30 | BLUE WATER LIFE SCIENCE ADVISORS, LP | 510.0K +— (+0.0%) | 9.61M +2.2M (+29.6%) | 0.97% +0.032 pp | 6.03% -0.735 pp | USD17.83 +5.7% | 7 qtrs — |
| 31 | BNP PARIBAS ARBITRAGE, SNC | 487.1K +293.6K (+151.8%) | 9.18M +6.4M (+226.3%) | 0.93% +0.571 pp | 0.00% +0.003 pp | USD17.54 +7.4% | 31 qtrs — |
| 32 | PALO ALTO INVESTORS LP | 478.2K +162.0K (+51.2%) | 9.01M +4.4M (+96.0%) | 0.91% +0.329 pp | 1.25% +0.403 pp | USD16.00 +17.8% | 2 qtrs — |
| 33 | NORTHERN TRUST CORP | 449.9K -42.9K (-8.7%) | 8.48M +1.3M (+18.3%) | 0.86% -0.051 pp | 0.00% +0.000 pp | USD20.62 -8.6% | 36 qtrs — |
| 34 | BELLEVUE GROUP AG | 431.1K -141.9K (-24.8%) | 8.12M -209.4K (-2.5%) | 0.82% -0.234 pp | 0.15% -0.019 pp | USD29.40 -35.9% | 30 qtrs — |
| 35 | JANE STREET GROUP, LLC | 430.2K +337.2K (+362.5%) | 8.11M +6.8M (+499.3%) | 0.82% +0.648 pp | 0.00% +0.001 pp | USD17.91 +5.2% | 22 qtrs — |
| 36 | RUSSELL INVESTMENTS GROUP, LTD. | 420.2K +167.5K (+66.3%) | 7.92M +4.2M (+115.4%) | 0.80% +0.335 pp | 0.01% +0.005 pp | USD21.47 -12.2% | 32 qtrs — |
| 37 | PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 375.0K -50.0K (-11.8%) | 7.07M +885.5K (+14.3%) | 0.71% -0.068 pp | 14.60% +3.578 pp | USD16.91 +11.4% | 4 qtrs — |
| 38 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 371.4K +— (+0.0%) | 7.00M +1.6M (+29.6%) | 0.71% +0.023 pp | 0.05% +0.012 pp | USD17.75 +6.1% | 4 qtrs — |
| 39 | ABRDN PLC | 345.3K +345.3K (+100.0%) | 6.51M +6.5M (+100.0%) | 0.66% +0.658 pp | 0.01% +0.010 pp | USD18.84 +0.0% | 1 qtrs NEW |
| 40 | NUVEEN, LLC | 333.9K +165.3K (+98.0%) | 6.29M +3.8M (+156.6%) | 0.64% +0.325 pp | 0.00% +0.001 pp | USD18.29 +3.0% | 4 qtrs — |
| 41 | BANK OF AMERICA CORP /DE/ | 324.8K +6.2K (+2.0%) | 6.12M +1.5M (+32.1%) | 0.62% +0.032 pp | 0.00% +0.000 pp | USD18.83 +0.1% | 32 qtrs — |
| 42 | AQR CAPITAL MANAGEMENT LLC | 303.0K +115.1K (+61.3%) | 5.71M +3.0M (+109.0%) | 0.58% +0.231 pp | 0.00% +0.001 pp | USD19.77 -4.7% | 31 qtrs — |
| 43 | JANUS HENDERSON GROUP PLC | 287.6K +265.7K (+1,213.1%) | 5.42M +5.1M (+1,602.0%) | 0.55% +0.507 pp | 0.00% +0.002 pp | USD19.78 -4.8% | 6 qtrs — |
| 44 | PARKMAN HEALTHCARE PARTNERS LLC | 276.2K +276.2K (+100.0%) | 5.20M +5.2M (+100.0%) | 0.53% +0.526 pp | 0.50% +0.495 pp | USD18.84 +0.0% | 1 qtrs NEW |
| 45 | PROSIGHT MANAGEMENT, LP | 250.0K -254.0K (-50.4%) | 4.71M -2.6M (-35.7%) | 0.48% -0.452 pp | 0.97% -0.736 pp | USD17.64 +6.8% | 5 qtrs — |
| 46 | BULLSEYE ASSET MANAGEMENT LLC | 235.5K +10.0K (+4.4%) | 4.44M +1.2M (+35.3%) | 0.45% +0.033 pp | 2.39% +0.674 pp | USD14.63 +28.8% | 23 qtrs — |
| 47 | MAN GROUP PLC | 233.2K +79.0K (+51.3%) | 4.39M +2.2M (+96.0%) | 0.44% +0.160 pp | 0.01% +0.004 pp | USD16.90 +11.5% | 13 qtrs — |
| 48 | LEGAL & GENERAL GROUP PLC | 230.5K +70.5K (+44.0%) | 4.34M +2.0M (+86.7%) | 0.44% +0.144 pp | 0.00% +0.000 pp | USD17.16 +9.8% | 31 qtrs — |
| 49 | FMR LLC | 209.4K +53.8K (+34.6%) | 3.95M +1.7M (+74.4%) | 0.40% +0.112 pp | 0.00% +0.000 pp | USD15.92 +18.3% | 27 qtrs — |
| 50 | FRED ALGER MANAGEMENT, LLC | 174.7K -754.3K (-81.2%) | 3.29M -10.2M (-75.6%) | 0.33% -1.378 pp | 0.01% -0.040 pp | USD18.69 +0.8% | 8 qtrs — |
| 51 | BANK OF NEW YORK MELLON CORP | 169.9K +15.1K (+9.8%) | 3.20M +950.7K (+42.2%) | 0.32% +0.039 pp | 0.00% +0.000 pp | USD23.56 -20.0% | 33 qtrs — |
| 52 | WELLINGTON MANAGEMENT GROUP LLP | 169.9K -14.7K (-8.0%) | 3.20M +516.0K (+19.2%) | 0.32% -0.017 pp | 0.00% +0.000 pp | USD11.95 +57.7% | 9 qtrs — |
| 53 | BARCLAYS PLC | 164.4K +65.9K (+66.9%) | 3.10M +21.7K (+0.7%) | 0.31% +0.132 pp | 0.00% +0.000 pp | USD20.91 -9.9% | 33 qtrs — |
| 54 | RAYMOND JAMES FINANCIAL INC | 162.0K -4.8K (-2.9%) | 3.05M +626.9K (+25.9%) | 0.31% +0.001 pp | 0.00% +0.000 pp | USD21.28 -11.5% | 5 qtrs — |
| 55 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 139.4K +120.7K (+645.2%) | 2.63M +2.4M (+865.6%) | 0.27% +0.231 pp | 0.00% +0.004 pp | USD21.12 -10.8% | 30 qtrs — |
| 56 | UBS ASSET MANAGEMENT AMERICAS INC | 125.2K -15.7K (-11.2%) | 2.36M +309.6K (+15.1%) | 0.24% -0.021 pp | 0.00% +0.000 pp | USD22.18 -15.1% | 6 qtrs — |
| 57 | STATE OF WISCONSIN INVESTMENT BOARD | 125.0K -43.7K (-25.9%) | 2.36M -98.1K (-4.0%) | 0.24% -0.073 pp | 0.01% 0.000 pp | USD17.64 +6.8% | 30 qtrs — |
| 58 | ENGINEERS GATE MANAGER LP | 120.4K +21.5K (+21.8%) | 2.27M +830.6K (+57.8%) | 0.23% +0.047 pp | 0.03% +0.010 pp | USD15.18 +24.1% | 13 qtrs — |
| 59 | UBS GROUP AG | 120.0K +8.6K (+7.7%) | 2.26M +640.8K (+39.5%) | 0.23% +0.023 pp | 0.00% +0.000 pp | USD17.15 +9.9% | 45 qtrs — |
| 60 | LAZARD ASSET MANAGEMENT LLC | 116.3K -10.0K (-7.9%) | 2.19M +354.2K (+19.3%) | 0.22% -0.011 pp | 0.00% +0.001 pp | USD19.49 -3.3% | 6 qtrs — |
| 61 | INVESCO LTD. | 115.5K +5.8K (+5.2%) | 2.18M +580.4K (+36.4%) | 0.22% +0.018 pp | 0.00% +0.000 pp | USD24.45 -22.9% | 31 qtrs — |
| 62 | FRANKLIN RESOURCES INC | 103.7K +3.8K (+3.8%) | 1.95M +500.8K (+34.5%) | 0.20% +0.014 pp | 0.00% +0.000 pp | USD17.16 +9.8% | 11 qtrs — |
| 63 | TWO SIGMA ADVISERS, LP | 102.3K +74.2K (+264.1%) | 1.93M +1.5M (+371.7%) | 0.19% +0.143 pp | 0.00% +0.003 pp | USD20.82 -9.5% | 33 qtrs — |
| 64 | JUMP FINANCIAL, LLC | 101.0K +67.8K (+204.9%) | 1.90M +1.4M (+295.1%) | 0.19% +0.131 pp | 0.02% +0.018 pp | USD17.43 +8.1% | 2 qtrs — |
| 65 | FORMULA GROWTH LTD | 100.7K -91.6K (-47.6%) | 1.90M -899.4K (-32.2%) | 0.19% -0.162 pp | 0.73% -0.264 pp | USD19.64 -4.1% | 5 qtrs — |
| 66 | BALYASNY ASSET MANAGEMENT L.P. | 99.9K +59.7K (+148.9%) | 1.88M +1.3M (+222.5%) | 0.19% +0.116 pp | 0.00% +0.002 pp | USD19.12 -1.5% | 3 qtrs — |
| 67 | MILLENNIUM MANAGEMENT LLC | 99.7K -314.0K (-75.9%) | 1.88M -4.1M (-68.8%) | 0.19% -0.572 pp | 0.00% -0.002 pp | USD14.96 +25.9% | 33 qtrs — |
| 68 | SWISS NATIONAL BANK | 99.7K -2.8K (-2.7%) | 1.88M +388.0K (+26.0%) | 0.19% +0.001 pp | 0.00% +0.000 pp | USD30.52 -38.3% | 6 qtrs — |
| 69 | ARS INVESTMENT PARTNERS, LLC | 94.3K -11.7K (-11.0%) | 1.78M +235.3K (+15.3%) | 0.18% -0.016 pp | 0.10% +0.002 pp | USD13.15 +43.3% | 12 qtrs — |
| 70 | RAFFERTY ASSET MANAGEMENT, LLC | 91.1K -1.4K (-1.5%) | 1.72M +372.0K (+27.7%) | 0.17% +0.003 pp | 0.01% +0.002 pp | USD18.37 +2.6% | 28 qtrs — |
| 71 | TWO SIGMA INVESTMENTS, LP | 89.3K +89.3K (+100.0%) | 1.68M +1.7M (+100.0%) | 0.17% +0.170 pp | 0.00% +0.002 pp | USD18.84 +0.0% | 23 qtrs — |
| 72 | AMERICAN CENTURY COMPANIES INC | 87.6K +16.0K (+22.3%) | 1.65M +609.1K (+58.5%) | 0.17% +0.035 pp | 0.00% +0.000 pp | USD15.32 +23.0% | 2 qtrs — |
| 73 | IQ EQ FUND MANAGEMENT (IRELAND) LTD | 83.5K +25.2K (+43.3%) | 1.57M +725.9K (+85.7%) | 0.16% +0.052 pp | 0.11% +0.051 pp | USD18.55 +1.6% | 6 qtrs — |
| 74 | GOTHAM ASSET MANAGEMENT, LLC | 82.6K +82.6K (+100.0%) | 1.56M +1.6M (+100.0%) | 0.16% +0.157 pp | 0.01% +0.006 pp | USD18.84 +0.0% | 1 qtrs NEW |
| 75 | GLOBEFLEX CAPITAL L P | 79.8K +8.8K (+12.4%) | 1.50M +471.0K (+45.6%) | 0.15% +0.021 pp | 0.23% +0.071 pp | USD29.00 -35.0% | 7 qtrs — |
| 76 | SCHONFELD STRATEGIC ADVISORS LLC | 78.8K +78.8K (+100.0%) | 1.49M +1.5M (+100.0%) | 0.15% +0.150 pp | 0.01% +0.007 pp | USD18.84 +0.0% | 3 qtrs — |
| 77 | PRINCIPAL FINANCIAL GROUP INC | 78.6K +24.5K (+45.2%) | 1.48M +694.0K (+88.1%) | 0.15% +0.050 pp | 0.00% +0.000 pp | USD21.58 -12.7% | 23 qtrs — |
| 78 | ALGERT GLOBAL LLC | 70.2K +27.8K (+65.8%) | 1.32M +707.0K (+115.0%) | 0.13% +0.056 pp | 0.02% +0.010 pp | USD20.72 -9.1% | 6 qtrs — |
| 79 | RHUMBLINE ADVISERS | 69.2K -12.7K (-15.5%) | 1.30M +112.7K (+9.5%) | 0.13% -0.019 pp | 0.00% +0.000 pp | USD20.14 -6.5% | 31 qtrs — |
| 80 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 61.5K -3.1K (-4.9%) | 1.16M +218.6K (+23.2%) | 0.12% -0.002 pp | 0.00% +0.000 pp | USD15.64 +20.5% | 7 qtrs — |
| 81 | WELLS FARGO & COMPANY/MN | 57.1K +23.5K (+70.1%) | 1.08M +588.0K (+120.4%) | 0.11% +0.047 pp | 0.00% +0.000 pp | USD16.49 +14.3% | 34 qtrs — |
| 82 | PRUDENTIAL FINANCIAL INC | 55.5K +11.4K (+25.9%) | 1.05M +404.5K (+63.1%) | 0.11% +0.025 pp | 0.00% +0.001 pp | USD18.67 +0.9% | 12 qtrs — |
| 83 | AMERIPRISE FINANCIAL INC | 52.5K +104.0 (+0.2%) | 990.0K +227.5K (+29.8%) | 0.10% +0.004 pp | 0.00% +0.000 pp | USD23.45 -19.7% | 30 qtrs — |
| 84 | AQUATIC CAPITAL MANAGEMENT LLC | 52.1K -37.7K (-42.0%) | 981.1K -323.7K (-24.8%) | 0.10% -0.066 pp | 0.03% +0.004 pp | USD14.65 +28.6% | 5 qtrs — |
| 85 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 47.5K -30.6K (-39.2%) | 895.7K -240.6K (-21.2%) | 0.09% -0.053 pp | 0.00% +0.000 pp | USD17.69 +6.5% | 27 qtrs — |
| 86 | ALLIANCEBERNSTEIN L.P. | 46.5K +— (+0.0%) | 875.3K +199.8K (+29.6%) | 0.09% +0.003 pp | 0.00% +0.000 pp | USD25.29 -25.5% | 31 qtrs — |
| 87 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 46.4K -482.0 (-1.0%) | 874.0K +192.5K (+28.2%) | 0.09% +0.002 pp | 0.00% +0.000 pp | USD30.60 -38.4% | 31 qtrs — |
| 88 | PALUMBO WEALTH MANAGEMENT LLC | 45.8K +8.8K (+23.7%) | 862.1K +324.4K (+60.3%) | 0.09% +0.019 pp | 0.21% +0.041 pp | USD15.36 +22.7% | 2 qtrs — |
| 89 | DEUTSCHE BANK AG\ | 45.1K -82.4K (-64.6%) | 850.5K -1.0M (-54.1%) | 0.09% -0.149 pp | 0.00% 0.000 pp | USD12.87 +46.4% | 33 qtrs — |
| 90 | EXCHANGE TRADED CONCEPTS, LLC | 43.6K -7.9K (-15.4%) | 821.2K +72.0K (+9.6%) | 0.08% -0.012 pp | 0.01% 0.000 pp | USD20.64 -8.7% | 22 qtrs — |
| 91 | VIRTUS ETF ADVISERS LLC | 40.6K +— (+0.0%) | 764.2K +174.4K (+29.6%) | 0.08% +0.003 pp | 0.36% +0.036 pp | USD17.75 +6.1% | 4 qtrs — |
| 92 | ACADIAN ASSET MANAGEMENT LLC | 40.6K +40.6K (+100.0%) | 760.0K +760.0K (+100.0%) | 0.08% +0.077 pp | 0.00% +0.001 pp | USD18.84 +0.0% | 11 qtrs — |
| 93 | JPMORGAN CHASE & CO | 39.5K -25.2K (-38.9%) | 744.3K -195.8K (-20.8%) | 0.08% -0.044 pp | 0.00% +0.000 pp | USD21.05 -10.5% | 37 qtrs — |
| 94 | PRICE T ROWE ASSOCIATES INC /MD/ | 39.2K +711.0 (+1.8%) | 739.0K +179.0K (+32.0%) | 0.07% +0.004 pp | 0.00% +0.000 pp | USD23.86 -21.0% | 29 qtrs — |
| 95 | CANADA PENSION PLAN INVESTMENT BOARD | 38.6K +38.6K (+100.0%) | 727.2K +727.2K (+100.0%) | 0.07% +0.074 pp | 0.00% +0.001 pp | USD18.84 +0.0% | 1 qtrs NEW |
| 96 | SQUAREPOINT OPS LLC | 38.1K -6.4K (-14.4%) | 718.2K +70.8K (+10.9%) | 0.07% -0.009 pp | 0.00% +0.000 pp | USD30.53 -38.3% | 31 qtrs — |
| 97 | PROFUND ADVISORS LLC | 33.9K +13.8K (+68.7%) | 638.1K +346.1K (+118.5%) | 0.06% +0.028 pp | 0.02% +0.010 pp | USD16.19 +16.4% | 12 qtrs — |
| 98 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 31.2K +31.2K (+100.0%) | 588.6K +588.6K (+100.0%) | 0.06% +0.060 pp | 0.00% +0.005 pp | USD18.84 +0.0% | 1 qtrs NEW |
| 99 | CREATIVE PLANNING | 29.6K +1.6K (+5.7%) | 557.3K +150.4K (+36.9%) | 0.06% +0.005 pp | 0.00% +0.000 pp | USD14.77 +27.6% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 113 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Biotechnology & Genome ETF PBE | 3.22% | 9.23M | 0.58% |
| 2 | ARK Genomic Revolution ETF ARKG | 2.82% | 36.90M | 0.75% |
| 3 | Global X - Genomics & Biotechnology ETF GNOM | 1.16% | 1.00M | 0.50% |
| 4 | Global X - Genomics & Biotechnology UCITS ETF GNOM.L | 1.15% | 603.9K | 0.50% |
| 5 | ROBO Global Healthcare Technology and Innovation ETF HTEC | 1.06% | 526.0K | 0.68% |
| 6 | Franklin Genomic Advancements ETF HELX | 0.81% | 244.3K | 0.50% |
| 7 | Janus Henderson Small Cap Growth Alpha ETF JSML | 0.67% | 2.48M | 0.30% |
| 8 | Janus Henderson Small/Mid Cap Growth Alpha ETF JSMD | 0.59% | 6.40M | 0.30% |
| 9 | iShares Micro-Cap ETF IWC | 0.33% | 4.90M | 0.60% |
| 10 | Global X - S&P Biotech ETF CURE.AX | 0.30% | 108.8K | 0.45% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.22
Bearish
Ratio by volume
0.19
Bearish
Buys
2
Sells
9
Shares acquired
26.1K
Shares disposed
137.9K
Cash buys
—
Cash sales
2.00
Net activity
-111,804
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | TORRES ARTHUR A | Director | S-Sale | D | Common Stock | 6,484 | 19.89 | 129.0K | 38,665 | D | ↗ |
| 2026-05-14 | TORRES ARTHUR A | Director | S-Sale | D | Common Stock | 4,086 | 20.97 | 85.7K | 45,149 | D | ↗ |
| 2026-05-05 | Novack Jeffrey Adam | Officer | S-Sale | D | Common Stock | 2,688 | 20.68 | 55.6K | 113,924 | D | ↗ |
| 2026-05-01 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 2,873 | 21.50 | 61.8K | 116,612 | D | ↗ |
| 2026-04-20 | Kennedy Keith | Officer | A-Award | A | Common Stock | 24,134 | 0.00 | — | 221,548 | D | ↗ |
| 2026-04-16 | Hanna John Walter JR | Director / Officer | S-Sale | D | Common Stock | 10,282 | 21.12 | 217.2K | 676,475 | D | ↗ |
| 2026-04-15 | Hanna John Walter JR | Director / Officer | F-InKind | D | Common Stock | 62,049 | 17.57 | 1.09M | 686,757 | D | ↗ |
| 2026-04-06 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 1,892 | 17.82 | 33.7K | 119,485 | D | ↗ |
| 2026-04-02 | Goldberg Michael | Director | A-Award | A | Common Stock | 1,981 | 0.00 | — | 185,942 | D | ↗ |
| 2026-04-01 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 3,987 | 17.87 | 71.2K | 121,377 | D | ↗ |
| 2026-04-01 | Meng Jessica | Officer | F-InKind | D | Common Stock | 7,386 | 17.87 | 132.0K | 169,392 | D | ↗ |
| 2026-04-01 | Kennedy Keith | Officer | F-InKind | D | Common Stock | 11,725 | 17.87 | 209.5K | 197,414 | D | ↗ |
| 2026-04-01 | Hanna John Walter JR | Director / Officer | F-InKind | D | Common Stock | 35,037 | 17.87 | 626.1K | 748,806 | D | ↗ |
| 2026-03-31 | Goldberg Michael | Director | M-Exempt | D | Stock Option (right to buy) | 5,255 | 5.02 | 26.4K | 0 | D | ↗ |
| 2026-02-03 | Novack Jeffrey Adam | Officer | S-Sale | D | Common Stock | 4,441 | 20.56 | 91.3K | 125,364 | D | ↗ |
| 2026-02-02 | SMITH NATHAN | Officer | A-Award | A | Common Stock | 33,000 | 0.00 | — | 75,000 | D | ↗ |
| 2026-02-02 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 2,970 | 20.42 | 60.6K | 129,805 | D | ↗ |
| 2026-02-02 | Meng Jessica | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 169,629 | D | ↗ |
| 2026-02-02 | Kennedy Keith | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 199,309 | D | ↗ |
| 2026-02-02 | Hanna John Walter JR | Director / Officer | A-Award | A | Common Stock | 162,500 | 0.00 | — | 759,905 | D | ↗ |
| 2026-01-22 | Hanna John Walter JR | Director / Officer | S-Sale | D | Common Stock | 19,280 | 21.16 | 408.0K | 597,405 | D | ↗ |
| 2026-01-21 | Hanna John Walter JR | Director / Officer | S-Sale | D | Common Stock | 200 | 21.00 | 4.2K | 616,685 | D | ↗ |
| 2026-01-15 | Hanna John Walter JR | Director / Officer | S-Sale | D | Common Stock | 10,156 | 21.05 | 213.8K | 616,885 | D | ↗ |
| 2026-01-06 | Goldberg Michael | Director | A-Award | A | Common Stock | 1,492 | 0.00 | — | 157,461 | D | ↗ |
| 2025-12-04 | Novack Jeffrey Adam | Officer | S-Sale | D | Common Stock | 7,007 | 19.15 | 134.2K | 98,211 | D | ↗ |
| 2025-11-07 | Novack Jeffrey Adam | Officer | S-Sale | D | Common Stock | 2,688 | 15.52 | 41.7K | 105,218 | D | ↗ |
| 2025-11-06 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 2,152 | 15.01 | 32.3K | 107,906 | D | ↗ |
| 2025-11-01 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 2,872 | 14.77 | 42.4K | 110,058 | D | ↗ |
| 2025-10-22 | Gunasekaran Suresh | Director | A-Award | A | Common Stock | 27,453 | 0.00 | — | 27,453 | D | ↗ |
| 2025-10-06 | Goldberg Michael | Director | A-Award | A | Common Stock | 1,753 | 0.00 | — | 155,969 | D | ↗ |
| 2025-09-12 | Meng Jessica | Officer | F-InKind | D | Common Stock | 4,703 | 13.53 | 63.6K | 109,629 | D | ↗ |
| 2025-09-12 | Kennedy Keith | Officer | F-InKind | D | Common Stock | 7,987 | 13.53 | 108.1K | 139,309 | D | ↗ |
| 2025-09-11 | Bickerstaff George | Director | M-Exempt | A | Common Stock | 29,136 | 7.96 | 231.9K | 144,266 | D | ↗ |
| 2025-08-07 | SMITH NATHAN | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-05 | Novack Jeffrey Adam | Officer | S-Sale | D | Common Stock | 2,688 | 12.79 | 34.4K | 112,930 | D | ↗ |
| 2025-08-01 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 2,873 | 12.22 | 35.1K | 115,618 | D | ↗ |
| 2025-08-01 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 7,687 | 12.22 | 93.9K | 319,725 | D | ↗ |
| 2025-07-08 | Goldberg Michael | Director | A-Award | A | Common Stock | 1,218 | 0.00 | — | 154,216 | D | ↗ |
| 2025-07-07 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 276 | 18.45 | 5.1K | 118,491 | D | ↗ |
| 2025-07-07 | Maag Peter | Director | S-Sale | D | Common Stock | 10,000 | 18.58 | 185.8K | 308,846 | D | ↗ |
| 2025-06-18 | Valantine Hannah | Director | S-Sale | D | Common Stock | 10,570 | 19.16 | 202.6K | 38,994 | D | ↗ |
| 2025-06-17 | Maag Peter | Director | S-Sale | D | Common Stock | 10,000 | 19.24 | 192.4K | 318,846 | D | ↗ |
| 2025-06-13 | Valantine Hannah | Director | A-Award | A | Common Stock | 12,103 | 0.00 | — | 49,564 | D | ↗ |
| 2025-06-13 | TORRES ARTHUR A | Director | A-Award | A | Common Stock | 12,103 | 0.00 | — | 49,235 | D | ↗ |
| 2025-06-13 | Riggsbee Richard Bryan | Director | A-Award | A | Common Stock | 12,103 | 0.00 | — | 29,517 | D | ↗ |
| 2025-06-13 | Maag Peter | Director | A-Award | A | Common Stock | 12,103 | 0.00 | — | 328,846 | D | ↗ |
| 2025-06-13 | Goldberg Michael | Director | A-Award | A | Common Stock | 12,103 | 0.00 | — | 152,998 | D | ↗ |
| 2025-06-13 | Cohen Fred E | Director | A-Award | A | Common Stock | 12,103 | 0.00 | — | 155,265 | D | ↗ |
| 2025-06-13 | COURNOYER CHRISTINE | Director | A-Award | A | Common Stock | 12,103 | 0.00 | — | 49,148 | D | ↗ |
| 2025-06-13 | Bickerstaff George | Director | A-Award | A | Common Stock | 12,103 | 0.00 | — | 115,130 | D | ↗ |
| 2025-06-11 | HAGSTROM WILLIAM A | Director | M-Exempt | A | Common Stock | 4,391 | 7.96 | 35.0K | 73,370 | D | ↗ |
| 2025-06-06 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 2,583 | 19.52 | 50.4K | 118,767 | D | ↗ |
| 2025-05-28 | HAGSTROM WILLIAM A | Director | M-Exempt | D | Stock Option (right to buy) | 510 | 5.85 | 3.0K | 0 | D | ↗ |
| 2025-05-27 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 1,982 | 17.63 | 34.9K | 327,412 | D | ↗ |
| 2025-05-12 | COURNOYER CHRISTINE | Director | M-Exempt | A | Common Stock | 29,136 | 7.96 | 231.9K | 66,181 | D | ↗ |
| 2025-05-06 | COURNOYER CHRISTINE | Director | S-Sale | D | Common Stock | 16,700 | 14.13 | 235.9K | 37,045 | D | ↗ |
| 2025-05-05 | Novack Jeffrey Adam | Officer | S-Sale | D | Common Stock | 2,688 | 14.70 | 39.5K | 121,350 | D | ↗ |
| 2025-05-01 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 2,873 | 15.07 | 43.3K | 124,038 | D | ↗ |
| 2025-05-01 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 7,686 | 15.07 | 115.8K | 329,394 | D | ↗ |
| 2025-04-30 | Maag Peter | Director | S-Sale | D | Common Stock | 13,281 | 17.23 | 228.8K | 316,743 | D | ↗ |
| 2025-04-21 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 338 | 16.94 | 5.7K | 337,080 | D | ↗ |
| 2025-04-15 | Hanna John Walter JR | Director / Officer | F-InKind | D | Common Stock | 61,469 | 19.16 | 1.18M | 627,041 | D | ↗ |
| 2025-04-07 | Novack Jeffrey Adam | Officer | S-Sale | D | Common Stock | 924 | 17.72 | 16.4K | 126,911 | D | ↗ |
| 2025-04-07 | Jain Abhishek | Officer | S-Sale | D | Common Stock | 265 | 17.72 | 4.7K | 337,418 | D | ↗ |
| 2025-04-04 | Goldberg Michael | Director | A-Award | A | Common Stock | 967 | 0.00 | — | 140,895 | D | ↗ |
| 2025-03-21 | Novack Jeffrey Adam | Officer | A-Award | A | Common Stock | 23,158 | 0.00 | — | 127,835 | D | ↗ |
| 2025-03-21 | Meng Jessica | Officer | A-Award | A | Common Stock | 61,756 | 0.00 | — | 114,332 | D | ↗ |
| 2025-03-21 | Kennedy Keith | Officer | A-Award | A | Common Stock | 77,195 | 0.00 | — | 147,296 | D | ↗ |
| 2025-03-21 | Jain Abhishek | Officer | A-Award | A | Common Stock | 55,580 | 0.00 | — | 337,683 | D | ↗ |
| 2025-03-21 | Hanna John Walter JR | Director / Officer | A-Award | A | Common Stock | 200,706 | 0.00 | — | 688,510 | D | ↗ |
| 2025-03-10 | Bickerstaff George | Director | S-Sale | D | Common Stock | 20,000 | 18.36 | 367.1K | 103,027 | D | ↗ |
| 2025-02-05 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 9,989 | 23.32 | 232.9K | 282,103 | D | ↗ |
| 2025-02-04 | Novack Jeffrey Adam | Officer | S-Sale | D | Common Stock | 3,512 | 23.30 | 81.8K | 104,677 | D | ↗ |
| 2025-02-03 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 2,048 | 23.32 | 47.8K | 108,189 | D | ↗ |
| 2025-02-03 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 11,244 | 23.32 | 262.2K | 254,292 | D | ↗ |
| 2025-01-06 | Goldberg Michael | Director | A-Award | A | Common Stock | 856 | 0.00 | — | 139,928 | D | ↗ |
| 2024-12-04 | Novack Jeffrey Adam | Officer | S-Sale | D | Common Stock | 1,917 | 26.00 | 49.8K | 110,237 | D | ↗ |
| 2024-11-26 | Maag Peter | Director | M-Exempt | A | Common Stock | 5,000 | 12.24 | 61.2K | 335,024 | D | ↗ |
| 2024-11-25 | Novack Jeffrey Adam | Officer | S-Sale | D | Common Stock | 365 | 24.00 | 8.8K | 113,012 | D | ↗ |
| 2024-11-18 | Novack Jeffrey Adam | Officer | S-Sale | D | Common Stock | 3,656 | 21.65 | 79.2K | 115,255 | D | ↗ |
| 2024-11-06 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 452 | 23.21 | 10.5K | 118,911 | D | ↗ |
| 2024-11-01 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 1,905 | 22.64 | 43.1K | 119,363 | D | ↗ |
| 2024-11-01 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 7,371 | 22.64 | 166.9K | 265,536 | D | ↗ |
| 2024-11-01 | Bickerstaff George | Director | M-Exempt | D | Stock Option (right to buy) | 2,226 | 5.49 | 12.2K | 0 | D | ↗ |
| 2024-10-04 | Goldberg Michael | Director | A-Award | A | Common Stock | 837 | 0.00 | — | 139,072 | D | ↗ |
| 2024-09-12 | Meng Jessica | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-12 | Kennedy Keith | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,651 | 29.43 | 2.96M | 100,651 | — | ↗ |
| 2024-09-09 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 2,807 | 27.43 | 77.0K | 272,907 | — | ↗ |
| 2024-09-06 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 697 | 27.10 | 18.9K | 275,714 | — | ↗ |
| 2024-08-21 | Johnson Alexander L | Officer | M-Exempt | A | Common Stock | 21,557 | 23.48 | 506.2K | 306,540 | — | ↗ |
| 2024-08-20 | Maag Peter | Director | M-Exempt | D | Employee Stock Option (right to buy) | 26,708 | 7.96 | 212.6K | 2,428 | — | ↗ |
| 2024-08-20 | Johnson Alexander L | Officer | S-Sale | D | Common Stock | 39,466 | 33.17 | 1.31M | 284,983 | — | ↗ |
| 2024-08-19 | Johnson Alexander L | Officer | S-Sale | D | Common Stock | 8,000 | 33.53 | 268.2K | 311,214 | — | ↗ |
| 2024-08-01 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 1,905 | 23.58 | 44.9K | 121,268 | — | ↗ |
| 2024-08-01 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 7,371 | 23.58 | 173.8K | 319,214 | — | ↗ |
| 2024-08-01 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 7,371 | 23.58 | 173.8K | 276,411 | — | ↗ |
| 2024-07-19 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 1,690 | 18.09 | 30.6K | 326,585 | — | ↗ |
| 2024-07-08 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 183 | 15.59 | 2.9K | 123,173 | — | ↗ |
| 2024-07-08 | Maag Peter | Director | A-Award | A | Common Stock | 1,034 | 0.00 | — | 338,868 | — | ↗ |
| 2024-07-08 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 634 | 15.59 | 9.9K | 328,275 | — | ↗ |
| 2024-07-08 | Goldberg Michael | Director | A-Award | A | Common Stock | 2,963 | 0.00 | — | 138,235 | — | ↗ |
| 2024-06-17 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 9,253 | 13.54 | 125.3K | 328,909 | — | ↗ |
| 2024-06-14 | Valantine Hannah | Director | A-Award | A | Stock Option (right to buy) | 16,048 | 9.35 | 150.0K | 16,048 | — | ↗ |
| 2024-06-14 | TORRES ARTHUR A | Director | A-Award | A | Common Stock | 10,570 | 0.00 | — | 37,132 | — | ↗ |
| 2024-06-14 | Riggsbee Richard Bryan | Director | A-Award | A | Common Stock | 10,570 | 0.00 | — | 17,414 | — | ↗ |
| 2024-06-14 | Maag Peter | Director | A-Award | A | Stock Option (right to buy) | 16,048 | 9.35 | 150.0K | 16,048 | — | ↗ |
| 2024-06-14 | HAGSTROM WILLIAM A | Director | A-Award | A | Stock Option (right to buy) | 16,048 | 9.35 | 150.0K | 16,048 | — | ↗ |
| 2024-06-14 | Goldberg Michael | Director | A-Award | A | Stock Option (right to buy) | 16,048 | 9.35 | 150.0K | 16,048 | — | ↗ |
| 2024-06-14 | Cohen Fred E | Director | A-Award | A | Stock Option (right to buy) | 16,048 | 9.35 | 150.0K | 16,048 | — | ↗ |
| 2024-06-14 | COURNOYER CHRISTINE | Director | A-Award | A | Stock Option (right to buy) | 16,048 | 14.19 | 227.7K | 16,048 | — | ↗ |
| 2024-06-14 | Bickerstaff George | Director | A-Award | A | Stock Option (right to buy) | 16,048 | 9.35 | 150.0K | 16,048 | — | ↗ |
| 2024-06-13 | Riggsbee Richard Bryan | Director | A-Award | A | Stock Option (right to buy) | 9,760 | 14.61 | 142.6K | 9,760 | — | ↗ |
| 2024-06-06 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 1,713 | 15.42 | 26.4K | 123,356 | — | ↗ |
| 2024-05-28 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 1,901 | 16.15 | 30.7K | 283,782 | — | ↗ |
| 2024-05-14 | Bickerstaff George | Director | M-Exempt | A | Common Stock | 5,255 | 10.00 | 52.6K | 104,976 | — | ↗ |
| 2024-05-01 | Novack Jeffrey Adam | Officer | F-InKind | D | Common Stock | 1,905 | 9.18 | 17.5K | 125,069 | — | ↗ |
| 2024-05-01 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 7,371 | 9.18 | 67.7K | 338,162 | — | ↗ |
| 2024-05-01 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 7,371 | 9.18 | 67.7K | 285,683 | — | ↗ |
| 2024-04-29 | Maag Peter | Director | M-Exempt | D | Employee Stock Option (right to buy) | 13,281 | 5.27 | 70.0K | 0 | — | ↗ |
| 2024-04-24 | Novack Jeffrey Adam | Officer | — | D | Employee Stock Option (right to buy) | 2,385 | 18.24 | 43.5K | 0 | — | ↗ |
| 2024-04-18 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 323 | 8.07 | 2.6K | 293,054 | — | ↗ |
| 2024-04-15 | Hanna John Walter JR | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 487,804 | — | ↗ |
| 2024-04-08 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 235 | 9.53 | 2.2K | 293,377 | — | ↗ |
| 2024-04-04 | Maag Peter | Director | A-Award | A | Common Stock | 1,249 | 0.00 | — | 313,983 | — | ↗ |
| 2024-04-04 | Goldberg Michael | Director | A-Award | A | Common Stock | 3,686 | 0.00 | — | 124,702 | — | ↗ |
| 2024-03-11 | Riggsbee Richard Bryan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-05 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 1,120 | 8.56 | 9.6K | 169,893 | — | ↗ |
| 2024-02-02 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 1,614 | 8.72 | 14.1K | 173,565 | — | ↗ |
| 2024-02-01 | Johnson Alexander L | Officer | A-Award | A | Common Stock | 174,520 | 0.00 | — | 345,533 | — | ↗ |
| 2024-02-01 | Jain Abhishek | Officer | A-Award | A | Common Stock | 174,520 | 0.00 | — | 293,612 | — | ↗ |
| 2024-01-29 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 1,120 | 9.88 | 11.1K | 186,424 | — | ↗ |
| 2024-01-12 | Goldberg Michael | Director | A-Award | A | Common Stock | 18,165 | 0.00 | — | 121,016 | — | ↗ |
| 2024-01-04 | Maag Peter | Director | A-Award | A | Common Stock | 1,525 | 0.00 | — | 312,734 | — | ↗ |
| 2024-01-04 | Goldberg Michael | Director | A-Award | A | Common Stock | 3,000 | 0.00 | — | 102,851 | — | ↗ |
| 2024-01-04 | COURNOYER CHRISTINE | Director | A-Award | A | Common Stock | 2,288 | 0.00 | — | 43,175 | — | ↗ |
| 2024-01-02 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 1,047 | 11.94 | 12.5K | 187,544 | — | ↗ |
| 2023-10-04 | Maag Peter | Director | A-Award | A | Common Stock | 1,552 | 0.00 | — | 311,209 | — | ↗ |
| 2023-10-04 | Goldberg Michael | Director | A-Award | A | Common Stock | 3,052 | 0.00 | — | 99,851 | — | ↗ |
| 2023-10-04 | COURNOYER CHRISTINE | Director | A-Award | A | Common Stock | 1,552 | 0.00 | — | 40,887 | — | ↗ |
| 2023-10-02 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 2,818 | 6.91 | 19.5K | 479,164 | — | ↗ |
| 2023-09-20 | Ronai Abraham | Officer | A-Award | A | Common Stock | 360,000 | 0.00 | — | 515,986 | — | ↗ |
| 2023-09-07 | Ronai Abraham | Officer | F-InKind | D | Common Stock | 1,465 | 8.26 | 12.1K | 155,986 | — | ↗ |
| 2023-09-07 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 2,746 | 8.26 | 22.7K | 130,561 | — | ↗ |
| 2023-09-06 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 1,054 | 8.81 | 9.3K | 133,307 | — | ↗ |
| 2023-09-05 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 2,819 | 9.49 | 26.8K | 481,982 | — | ↗ |
| 2023-08-14 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 576 | 8.89 | 5.1K | 484,801 | — | ↗ |
| 2023-08-11 | Bickerstaff George | Director | M-Exempt | D | Option to Purchase Common Stock | 4,453 | 5.49 | 24.4K | 2,226 | — | ↗ |
| 2023-08-07 | Seeto Reginald | Director / Officer | F-InKind | D | Common Stock | 674 | 10.80 | 7.3K | 485,377 | — | ↗ |
| 2023-08-07 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 217 | 10.80 | 2.3K | 188,591 | — | ↗ |
| 2023-08-02 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 2,733 | 11.37 | 31.1K | 486,137 | — | ↗ |
| 2023-07-19 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 1,163 | 10.28 | 12.0K | 188,808 | — | ↗ |
| 2023-07-13 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 5,260 | 10.33 | 54.4K | 488,870 | — | ↗ |
| 2023-07-13 | Maag Peter | Director | S-Sale | D | Common Stock | 5,000 | 10.34 | 51.7K | 309,657 | — | ↗ |
| 2023-07-06 | Seeto Reginald | Director / Officer | F-InKind | D | Common Stock | 4,740 | 8.37 | 39.7K | 493,315 | — | ↗ |
| 2023-07-06 | Maag Peter | Director | A-Award | A | Common Stock | 1,521 | 0.00 | — | 314,657 | — | ↗ |
| 2023-07-06 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 422 | 8.37 | 3.5K | 189,971 | — | ↗ |
| 2023-07-06 | Goldberg Michael | Director | A-Award | A | Common Stock | 2,992 | 0.00 | — | 96,799 | — | ↗ |
| 2023-07-03 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 2,818 | 8.48 | 23.9K | 498,055 | — | ↗ |
| 2023-06-28 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 14,268 | 8.76 | 125.0K | 500,873 | — | ↗ |
| 2023-06-28 | Maag Peter | Director | S-Sale | D | Common Stock | 2,432 | 8.72 | 21.2K | 313,136 | — | ↗ |
| 2023-06-16 | Valantine Hannah | Director | A-Award | A | Common Stock | 18,844 | 0.00 | — | 26,891 | — | ↗ |
| 2023-06-16 | TORRES ARTHUR A | Director | A-Award | A | Common Stock | 18,844 | 0.00 | — | 26,562 | — | ↗ |
| 2023-06-16 | Seeto Reginald | Director / Officer | F-InKind | D | Common Stock | 17,036 | 7.96 | 135.6K | 515,141 | — | ↗ |
| 2023-06-16 | Ronai Abraham | Officer | F-InKind | D | Common Stock | 3,611 | 7.96 | 28.7K | 155,199 | — | ↗ |
| 2023-06-16 | Maag Peter | Director | A-Award | A | Common Stock | 29,136 | 7.96 | 231.9K | 29,136 | — | ↗ |
| 2023-06-16 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 6,343 | 7.96 | 50.5K | 190,393 | — | ↗ |
| 2023-06-16 | HAGSTROM WILLIAM A | Director | A-Award | A | Common Stock | 29,136 | 7.96 | 231.9K | 29,136 | — | ↗ |
| 2023-06-16 | Goldberg Michael | Director | A-Award | A | Common Stock | 18,844 | 0.00 | — | 93,807 | — | ↗ |
| 2023-06-16 | Colon Grace | Director | A-Award | A | Common Stock | 18,844 | 0.00 | — | 23,708 | — | ↗ |
| 2023-06-16 | Cohen Fred E | Director | A-Award | A | Common Stock | 29,136 | 7.96 | 231.9K | 29,136 | — | ↗ |
| 2023-06-16 | COURNOYER CHRISTINE | Director | A-Award | A | Common Stock | 18,844 | 0.00 | — | 39,335 | — | ↗ |
| 2023-06-16 | Bickerstaff George | Director | A-Award | A | Common Stock | 29,136 | 7.96 | 231.9K | 29,136 | — | ↗ |
| 2023-06-05 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 433 | 7.98 | 3.5K | 196,736 | — | ↗ |
| 2023-06-02 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 2,819 | 8.13 | 22.9K | 532,177 | — | ↗ |
| 2023-05-26 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 1,297 | 7.96 | 10.3K | 132,109 | — | ↗ |
| 2023-05-02 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 2,819 | 8.12 | 22.9K | 534,996 | — | ↗ |
| 2023-04-18 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 221 | 9.07 | 2.0K | 133,406 | — | ↗ |
| 2023-04-11 | Maag Peter | Director | A-Award | A | Common Stock | 1,256 | 0.00 | — | 296,724 | — | ↗ |
| 2023-04-11 | Goldberg Michael | Director | A-Award | A | Common Stock | 2,391 | 0.00 | — | 74,963 | — | ↗ |
| 2023-04-06 | Jain Abhishek | Officer | F-InKind | D | Common Stock | 173 | 8.81 | 1.5K | 133,627 | — | ↗ |
| 2023-04-03 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 2,818 | 8.95 | 25.2K | 537,815 | — | ↗ |
| 2023-03-02 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 2,819 | 15.88 | 44.8K | 540,633 | — | ↗ |
| 2023-02-10 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 8,488 | 15.48 | 131.4K | 543,452 | — | ↗ |
| 2023-02-09 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 11,094 | 16.13 | 178.9K | 551,940 | — | ↗ |
| 2023-02-08 | Maag Peter | Director | S-Sale | D | Common Stock | 3,269 | 15.75 | 51.5K | 295,468 | — | ↗ |
| 2023-02-07 | Seeto Reginald | Director / Officer | S-Sale | D | Common Stock | 3,069 | 16.40 | 50.3K | 563,034 | — | ↗ |
| 2023-02-03 | Seeto Reginald | Director / Officer | F-InKind | D | Common Stock | 1,228 | 16.54 | 20.3K | 566,103 | — | ↗ |
| 2023-02-03 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 417 | 16.54 | 6.9K | 197,169 | — | ↗ |
| 2023-02-02 | Seeto Reginald | Director / Officer | F-InKind | D | Common Stock | 7,244 | 17.61 | 127.6K | 568,559 | — | ↗ |
| 2023-02-02 | Ronai Abraham | Officer | F-InKind | D | Common Stock | 2,029 | 17.61 | 35.7K | 158,810 | — | ↗ |
| 2023-02-02 | Maag Peter | Director | S-Sale | D | Common Stock | 5,000 | 17.17 | 85.8K | 298,737 | — | ↗ |
| 2023-02-02 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 2,029 | 17.61 | 35.7K | 198,003 | — | ↗ |
| 2023-02-01 | Seeto Reginald | Director / Officer | A-Award | A | Stock Option (right to buy) | 156,000 | 15.66 | 2.44M | 156,000 | — | ↗ |
| 2023-02-01 | Ronai Abraham | Officer | A-Award | A | Common Stock | 85,100 | 0.00 | — | 160,839 | — | ↗ |
| 2023-02-01 | Maag Peter | Director | A-Award | A | Common Stock | 5,230 | 0.00 | — | 303,737 | — | ↗ |
| 2023-02-01 | Johnson Alexander L | Officer | A-Award | A | Stock Option (right to buy) | 44,100 | 15.66 | 690.6K | 44,100 | — | ↗ |
| 2023-02-01 | Jain Abhishek | Officer | A-Award | A | Stock Option (right to buy) | 44,100 | 15.66 | 690.6K | 44,100 | — | ↗ |
| 2023-01-30 | Seeto Reginald | Director / Officer | F-InKind | D | Common Stock | 1,931 | 14.65 | 28.3K | 266,975 | — | ↗ |
| 2023-01-30 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 820 | 14.65 | 12.0K | 112,350 | — | ↗ |
| 2023-01-25 | Johnson Alexander L | Officer | F-InKind | D | Common Stock | 1,011 | 15.03 | 15.2K | 113,170 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-32.7K
Shares Outstanding
51.66M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | John W. Hanna President and Chief Executive Officer | 693.3K | — | 5.62M | — | 852.5K | 11.3K | 7.18M | 78.31% | ↗ |
| 2 | 2025 | Keith Kennedy Chief Operating Officer and Chief Financial Officer | 587.6K | — | 2.16M | — | 430.3K | 38.8K | 3.22M | 67.18% | ↗ |
| 3 | 2025 | Abhishek Jain Former Chief Financial Officer | 282.1K | — | 1.56M | — | 309.5K | 489.3K | 2.64M | 59.02% | ↗ |
| 4 | 2025 | Jessica Meng Chief Commercial Officer | 485.4K | — | 1.73M | — | 353.7K | 10.2K | 2.58M | 67.07% | ↗ |
| 5 | 2025 | Jeffrey Novack General Counsel and Secretary | 361.9K | — | 648.8K | — | 216.4K | 12.5K | 1.24M | 52.34% | ↗ |
| 6 | 2025 | Nathan Smith Former Chief Financial Officer | 141.5K | — | 724.2K | — | 91.6K | 10.6K | 968.0K | 74.82% | ↗ |
| 7 | 2024 | John W. Hanna President and Chief Executive Officer | 454.3K | — | 4.00M | 4.00M | 960.6K | 8.4K | 9.42M | 84.90% | ↗ |
| 8 | 2024 | Keith Kennedy Chief Operating Officer | 148.2K | — | 2.06M | 2.06M | 204.3K | 33.3K | 4.51M | 91.45% | ↗ |
| 9 | 2024 | Keith Kennedy Chief Operating Officer and Chief Financial Officer | 148.2K | — | 2.06M | 2.06M | 204.3K | 33.3K | 4.51M | 91.45% | ↗ |
| 10 | 2024 | Jessica Meng Chief Commercial Officer | 122.4K | — | 1.55M | 1.55M | 168.8K | 6.5K | 3.39M | 91.22% | ↗ |
| 11 | 2024 | Alexander Johnson Former President of Patient and Testing Services | 335.3K | — | 1.55M | — | — | 1.05M | 2.94M | 52.76% | ↗ |
| 12 | 2024 | Abhishek Jain Former Chief Financial Officer | 411.2K | 300.0K | 1.55M | — | 493.4K | 8.4K | 2.76M | 56.09% | ↗ |
| 13 | 2024 | Abhishek Jain Chief Financial Officer | 411.2K | 300.0K | 1.55M | — | 493.4K | 8.4K | 2.76M | 56.09% | ↗ |
| 14 | 2024 | Jeffrey Novack General Counsel and Secretary | 326.9K | 75.0K | 592.5K | — | 272.0K | 10.4K | 1.28M | 46.41% | ↗ |
| 15 | 2023 | Reginald Seeto, MBBS Former Chief Executive Officer and President | 556.8K | — | 6.83M | 1.70M | — | 1.46M | 10.55M | 80.90% | ↗ |
| 16 | 2023 | Abraham Ronai Former Chief Administrative & Legal Officer and Secretary | 331.0K | — | 4.39M | 482.0K | — | 933.8K | 6.14M | 79.40% | ↗ |
| 17 | 2023 | Alex Johnson President of President and Testing Services | 408.3K | 100.0K | 1.92M | 482.0K | 174.3K | 8.3K | 3.10M | 77.70% | ↗ |
| 18 | 2023 | Alexander Johnson Former President of Patient and Testing Services | 408.3K | 100.0K | 1.92M | 482.0K | 174.3K | 8.3K | 3.10M | 77.70% | ↗ |
| 19 | 2023 | Abhishek Jain Chief Financial Officer | 405.0K | 100.0K | 1.92M | 482.0K | 174.3K | 8.8K | 3.09M | 77.76% | ↗ |
| 20 | 2023 | Abhishek Jain Former Chief Financial Officer | 405.0K | 100.0K | 1.92M | 482.0K | 174.3K | 8.8K | 3.09M | 77.76% | ↗ |
| 21 | 2022 | Reginald Seeto, MBBS Chief Executive Officer and President | 554.2K | — | 6.75M | 5.09M | 399.6K | 920.00 | 12.79M | 92.53% | ↗ |
| 22 | 2022 | Reginald Seeto, MBBS Former Chief Executive Officer and President | 554.2K | — | 6.75M | 5.09M | 399.6K | 920.00 | 12.79M | 92.53% | ↗ |
| 23 | 2022 | Alexander Johnson Former President of Patient and Testing Services | 384.8K | — | 2.52M | 2.66M | 161.5K | 1.1K | 5.72M | 90.44% | ↗ |
| 24 | 2022 | Alex Johnson President of President and Testing Services | 384.8K | — | 2.52M | 2.66M | 161.5K | 1.1K | 5.72M | 90.44% | ↗ |
| 25 | 2022 | Abraham Ronai Chief Administrative & Legal Officer and Secretary | 384.8K | — | 2.19M | 1.94M | 181.6K | — | 4.69M | 87.93% | ↗ |
| 26 | 2022 | Abraham Ronai Former Chief Administrative & Legal Officer and Secretary | 384.8K | — | 2.19M | 1.94M | 181.6K | — | 4.69M | 87.93% | ↗ |
| 27 | 2022 | Sasha King Former Chief Marketing Officer | 243.7K | — | 1.85M | 1.68M | — | 715.00 | 3.78M | 93.53% | ↗ |
| 28 | 2022 | Ankur Dhingra Former Chief Financial Officer | 184.9K | — | 1.23M | 967.4K | — | 400.00 | 2.39M | 92.23% | ↗ |
| 29 | 2022 | Abhishek Jain Chief Financial Officer | 318.9K | — | 904.7K | 1.01M | 104.3K | 2.4K | 2.34M | 81.84% | ↗ |
| 30 | 2021 | Reginald Seeto, MBBS Chief Executive Officer and President | 540.0K | — | 3.87M | 1.71M | 972.0K | 1.4K | 7.09M | 78.65% | ↗ |
| 31 | 2021 | Reginald Seeto, MBBS Former Chief Executive Officer and President | 540.0K | — | 3.87M | 1.71M | 972.0K | 1.4K | 7.09M | 78.65% | ↗ |
| 32 | 2021 | Alex Johnson Chief Business Officer | 332.9K | — | 2.09M | 1.16M | 382.1K | 1.6K | 3.97M | 81.94% | ↗ |
| 33 | 2021 | Alex Johnson President of President and Testing Services | 332.9K | — | 2.09M | 1.16M | 382.1K | 1.6K | 3.97M | 81.94% | ↗ |
| 34 | 2021 | Ankur Dhingra Chief Financial Officer | 306.9K | 100.0K | 1.08M | 1.28M | 501.6K | 720.00 | 3.27M | 72.17% | ↗ |
| 35 | 2021 | Ankur Dhingra Former Chief Financial Officer | 306.9K | 100.0K | 1.08M | 1.28M | 501.6K | 720.00 | 3.27M | 72.17% | ↗ |
| 36 | 2021 | Peter Maag, Ph.D., Former Executive Chair | 270.0K | — | 1.71M | 758.2K | 427.5K | 40.0K | 3.21M | 77.02% | ↗ |
| 37 | 2021 | Sasha King Chief Marketing Officer | 287.2K | — | 884.6K | 391.4K | 340.1K | 1.6K | 1.90M | 66.99% | ↗ |
| 38 | 2021 | Sasha King Former Chief Marketing Officer | 287.2K | — | 884.6K | 391.4K | 340.1K | 1.6K | 1.90M | 66.99% | ↗ |
| 39 | 2021 | Marcel Konrad Former Interim Chief Financial Officer | 160.5K | 764.00 | 511.9K | — | — | 6.7K | 679.9K | 75.30% | ↗ |
| 40 | 2020 | Peter Maag, Ph.D., Executive Chair and Former Chief Executive Officer | 488.7K | — | 3.33M | 1.72M | 860.2K | 1.6K | 6.40M | 78.90% | ↗ |
| 41 | 2020 | Peter Maag, Ph.D., Former Executive Chair | 488.7K | — | 3.33M | 1.72M | 860.2K | 1.6K | 6.40M | 78.90% | ↗ |
| 42 | 2020 | Reginald Seeto, MBBS Chief Executive Officer, President and Chief Business Officer | 429.2K | — | 2.94M | 1.69M | 558.8K | 1.1K | 5.62M | 82.40% | ↗ |
| 43 | 2020 | Reginald Seeto, MBBS Chief Executive Officer and President | 429.2K | — | 2.94M | 1.69M | 558.8K | 1.1K | 5.62M | 82.40% | ↗ |
| 44 | 2020 | Michael Bell Former Chief Financial Officer | 383.2K | — | 2.11M | 930.2K | — | 20.4K | 3.44M | 88.28% | ↗ |
| 45 | 2020 | Sasha King, M.B.A. Chief Marketing Officer | 305.1K | — | 562.1K | 310.3K | 362.1K | 1.6K | 1.54M | 56.60% | ↗ |
| 46 | 2020 | Sasha King Chief Marketing Officer | 305.1K | — | 562.1K | 310.3K | 362.1K | 1.6K | 1.54M | 56.60% | ↗ |
| 47 | 2020 | Sasha King Former Chief Marketing Officer | 305.1K | — | 562.1K | 310.3K | 362.1K | 1.6K | 1.54M | 56.60% | ↗ |
| 48 | 2020 | Marcel Konrad, M.B.A. Former Interim Chief Financial Officer | 283.7K | — | 409.6K | 106.4K | 152.9K | 960.00 | 953.5K | 54.11% | ↗ |
| 49 | 2020 | Marcel Konrad Former Interim Chief Financial Officer | 283.7K | — | 409.6K | 106.4K | 152.9K | 960.00 | 953.5K | 54.11% | ↗ |
| 50 | 2019 | Peter Maag, Ph.D., Executive Chair and Former Chief Executive Officer | 510.0K | — | 6.67M | 1.67M | 568.3K | 1.6K | 9.42M | 88.54% | ↗ |
| 51 | 2019 | Peter Maag, Ph.D., Former Executive Chair | 510.0K | — | 6.67M | 1.67M | 568.3K | 1.6K | 9.42M | 88.54% | ↗ |
| 52 | 2019 | Peter Maag, Ph.D., Chairman and Chief Executive Officer | 510.0K | — | 6.67M | 1.67M | 568.3K | 1.6K | 9.42M | 88.54% | ↗ |
| 53 | 2019 | Michael Bell Former Chief Financial Officer | 355.4K | — | 1.44M | 556.9K | 327.6K | 3.6K | 2.69M | 74.44% | ↗ |
| 54 | 2019 | Michael Bell Chief Financial Officer | 355.4K | — | 1.44M | 556.9K | 327.6K | 3.6K | 2.69M | 74.44% | ↗ |
| 55 | 2019 | Reginald Seeto, MBBS Chief Executive Officer and President | 400.0K | — | 572.8K | 556.9K | 425.0K | 960.00 | 1.96M | 57.76% | ↗ |
| 56 | 2019 | Reginald Seeto, MBBS Chief Executive Officer, President and Chief Business Officer | 400.0K | — | 572.8K | 556.9K | 425.0K | 960.00 | 1.96M | 57.76% | ↗ |
| 57 | 2019 | Reginald Seeto, MBBS President and Chief Business Officer | 400.0K | — | 572.8K | 556.9K | 425.0K | 960.00 | 1.96M | 57.76% | ↗ |
| 58 | 2019 | Sasha King Chief Marketing Officer | 283.8K | — | 721.1K | 278.4K | 216.4K | 9.0K | 1.51M | 66.25% | ↗ |
| 59 | 2019 | Sasha King, M.B.A. Chief Marketing Officer | 283.8K | — | 721.1K | 278.4K | 216.4K | 9.0K | 1.51M | 66.25% | ↗ |
| 60 | 2019 | James P. Yee, M.D., Ph.D. Former Chief Medical Officer | 247.4K | — | 652.1K | 278.4K | — | 300.00 | 1.18M | 78.98% | ↗ |
| 61 | 2018 | Peter Maag, Ph.D., Chief Executive Officer | 483.8K | — | 2.73M | 1.32M | 693.0K | 1.6K | 5.23M | 77.48% | ↗ |
| 62 | 2018 | Peter Maag, Ph.D., Executive Chair and Former Chief Executive Officer | 483.8K | — | 2.73M | 1.32M | 693.0K | 1.6K | 5.23M | 77.48% | ↗ |
| 63 | 2018 | Reginald Seeto, MBBS President and Chief Business Officer | 40.9K | — | 1.39M | 1.71M | 30.0K | 80.00 | 3.17M | 97.76% | ↗ |
| 64 | 2018 | Reginald Seeto, MBBS Chief Executive Officer, President and Chief Business Officer | 40.9K | — | 1.39M | 1.71M | 30.0K | 80.00 | 3.17M | 97.76% | ↗ |
| 65 | 2018 | Michael Bell Former Chief Financial Officer | 340.7K | — | 1.01M | 438.1K | 308.3K | 1.6K | 2.10M | 68.95% | ↗ |
| 66 | 2018 | Michael Bell Chief Financial Officer | 340.7K | — | 1.01M | 438.1K | 308.3K | 1.6K | 2.10M | 68.95% | ↗ |
| 67 | 2017 | Peter Maag, Ph.D., President and Chief Executive Officer | 450.0K | — | 306.9K | 264.8K | 378.0K | 1.6K | 1.40M | 40.80% | ↗ |
| 68 | 2017 | Peter Maag, Ph.D., Chief Executive Officer | 450.0K | — | 306.9K | 264.8K | 378.0K | 1.6K | 1.40M | 40.80% | ↗ |
| 69 | 2017 | James P. Yee, M.D., Ph.D., Chief Medical Officer | 382.9K | — | 82.0K | 47.8K | 184.8K | — | 697.5K | 18.61% | ↗ |
| 70 | 2017 | Michael Bell Chief Financial Officer | 237.3K | — | 147.5K | 190.5K | 114.3K | 1.1K | 690.8K | 48.94% | ↗ |
| 71 | 2016 | Peter Maag, Ph.D., President and Chief Executive Officer | 450.0K | — | 112.0K | 135.3K | 185.6K | — | 883.0K | 28.01% | ↗ |
| 72 | 2016 | Peter Maag, President and Chief Executive Officer | 450.0K | — | 112.0K | 135.3K | 185.6K | — | 883.0K | 28.01% | ↗ |
| 73 | 2016 | James P. Yee, M.D., Ph.D., Chief Medical Officer | 376.6K | — | 58.0K | 86.7K | 113.0K | — | 634.3K | 22.81% | ↗ |
| 74 | 2016 | James P. Yee, Chief Medical Officer | 376.6K | — | 58.0K | 86.7K | 113.0K | — | 634.3K | 22.81% | ↗ |
| 75 | 2016 | Mitchell J. Nelles, Chief Operating Officer | 325.0K | — | 58.0K | 70.1K | 97.5K | — | 550.5K | 23.26% | ↗ |
| 76 | 2015 | Peter Maag, President and Chief Executive Officer | 438.5K | — | 162.3K | 216.8K | 185.6K | 3.8K | 1.01M | 37.64% | ↗ |
| 77 | 2015 | Ken Ludlum, Former Chief Financial Officer and Senior Financial Advisor | 321.4K | — | 194.7K | 108.4K | 65.0K | 6.5K | 696.0K | 43.55% | ↗ |
| 78 | 2015 | John Sninsky , Chief Scientific Officer | 327.0K | — | — | 203.3K | 125.8K | 6.5K | 662.6K | 30.68% | ↗ |
| 79 | 2014 | Peter Maag, President and Chief Executive Officer | 370.7K | — | — | 535.2K | 176.9K | — | 1.08M | 49.42% | ↗ |
| 80 | 2014 | James Yee, Chief Medical Officer | 373.9K | 150.6K | — | 102.9K | — | — | 627.4K | 16.40% | ↗ |
| 81 | 2014 | Matthew Meyer, Chief Business Officer | 317.5K | 128.0K | — | 68.6K | — | — | 514.1K | 13.34% | ↗ |
| 82 | 2014 | Ken Ludlum, Former Chief Financial Officer and Senior Financial Advisor | 238.1K | — | — | — | 123.0K | — | 361.1K | 0.00% | ↗ |
| 83 | 2013 | Peter Maag, President and Chief Executive Officer | 350.0K | 190.0K | — | — | — | — | 540.0K | 0.00% | ↗ |
| 84 | 2013 | James Yee, Chief Medical Officer | 365.7K | 146.3K | — | — | — | — | 511.9K | 0.00% | ↗ |
| 85 | 2013 | Matthew Meyer, Chief Business Officer | 308.3K | 123.3K | — | — | — | — | 431.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Walter Hanna Jr. | President, Chief Executive Officer & Director | 2M | male |
| Keith S. Kennedy | CFO & COO | 1M | male |
| Jessica Meng | Chief Commercial Officer | 849.3K | female |
| Jeffrey A. Novack | General Counsel & Secretary | 590.8K | male |
| Kashif Rathore | Chief Technology Officer | — | male |
| Marica Grskovic | Chief Strategy Officer | — | female |
| Natasha Moshirian Wagner | Vice President of Corporate Communications | — | female |
| Robert N. Woodward | Chief Scientific Officer | — | — |
| Caroline Corner | Investor Relations | — | — |
| Tina Jacobsen | Vice President of Investor Relations | — | female |
| Jeffrey John Teuteberg | Chief Medical Officer | — | — |
| Jennifer Foley | Chief Product Officer | — | female |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2023-03-06 | 2023-04-17 | Daniel Goldman | NY10 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2021-12-29 | 2021-08-26 | Tom Malinowski | NJ07 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2021-03-02 | 2021-04-10 | Tom Malinowski | NJ07 | — | Purchase | $15,001 - $50,000 | ↗ |
| 2021-01-11 | 2021-08-26 | Tom Malinowski | NJ07 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2021-01-08 | 2021-08-26 | Tom Malinowski | NJ07 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2021-01-06 | 2021-08-26 | Tom Malinowski | NJ07 | — | Sale (Partial) | $15,001 - $50,000 | ↗ |
| 2020-12-23 | 2021-08-26 | Tom Malinowski | NJ07 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2020-12-07 | 2021-08-26 | Tom Malinowski | NJ07 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2020-11-16 | 2021-08-26 | Tom Malinowski | NJ07 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2020-10-09 | 2021-08-26 | Tom Malinowski | NJ07 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CDNA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
